Experiences with
Tabrecta2 public posts
New drug approval for MET exon 14 skipping mutation
"On May 6, 2020, the Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an
Want to take advantage of all our features? Just log in!
or